Long-Term Post Thrombotic Syndrome Assessment (CELEST Long Term).

Launched by LABORATOIRES INNOTHERA · Sep 19, 2023

Keywords

ClinConnect Summary

The CELEST Long-Term study is looking into a condition called post-thrombotic syndrome (PTS), which can occur after patients have experienced a blood clot in their leg (known as a deep vein thrombosis, or DVT). This study will follow patients who were part of the earlier CELEST trial for a total of seven years to see how many develop moderate to severe PTS. Researchers will also explore how different strengths of compression stockings used during their initial treatment may affect their risk of developing this condition.

To participate, individuals must have been part of the CELEST trial and be between the ages of 65 and 99 years old. They will receive a phone call for their follow-up visit, where they’ll be asked about their symptoms and experiences. It’s important to note that those who withdrew from the earlier trial or have serious memory problems may not be able to take part in this long-term assessment. This study aims to enhance understanding of PTS and potentially improve treatment options for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients enrolled and followed in the CELEST RCT\*
• Exclusion Criteria:
• • Patients who withdrew consent or died during the 2-year follow-up of the CELEST RCT.
• • Patients who decline or are unable to participate (including severe memory loss issues) to the long-term follow-up
• • CELEST RCT main inclusion/exclusion criteria were: adult (\>18 years at time of enrolment) patients first unilateral acute symptomatic proximal lower limb DVT